Scarica l'app Stockscreener
109.35
0.88%
0.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Novartis Ag Adr Borsa (NVS) Ultime notizie
Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis
Novartis on Pace for Largest Percent Decrease Since March 2021 — Data Talk - Morningstar
Chemical Biology in Biomedical Research - Novartis
Radioligand therapy: delivering now, building for the future - Novartis
Novartis Financial Results – Q2 2024 - Novartis
Inclusivity - Novartis
Collaborations - Novartis
Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial - GlobeNewswire Inc.
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
Novo Nordisk A/S (NVO) Stock Price, News, Quote & History - Yahoo Finance
5 Large Drug Stocks Likely To Outpace Q3 Earnings Estimates - Barchart
21 Best Healthcare Companies to Invest In - Morningstar
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move - sharewise
Saudi Arabia Generic Pharmaceutical Products Market Report 2024-2031, Featuring Profiles of Key Players - GlobeNewswire Inc.
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Roche Wins FDA Nod For Breast Cancer Drug In First-Line Setting - Barchart
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Europe Pruritus Therapeutics Market Size & Outlook, 2030 - Grand View Research
Norway Aspergillosis Treatment Market Size & Outlook, 2030 - Grand View Research
Precidian to List First ADRhedged Securities in the U.S. on Cboe - Traders Magazine
NVS: 3 European Stocks to Watch as the EU Economy Strengthens - StockNews.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-term Growth - Morningstar
Europe Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Australia Alzheimers Therapeutics Market Size & Outlook, 2030 - Grand View Research
Novartis Wins FDA Approval Of Kisqali For Early Breast Cancer - Barchart
Novartis' Kisqali Lowers Risk Of Breast Cancer Recurrence By 28% - Barchart
North America Immune Health Supplements Market Size & Outlook, 2030 - Grand View Research
Weekly Upgrades and Downgrades - InvestorPlace
Top investors say Novartis AG ADR (NVS) ticks everything they need - SETE News
Novartis lower as BofA downgrades on risks to valuation - MSN
Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - GlobeNewswire Inc.
Morgan Stanley cuts Novartis rating amid limited innovation - Baystreet.ca
Spain Congestive Heart Failure Drugs Market Size & Outlook, 2030 - Grand View Research
Market Insight: Novartis AG ADR (NVS)’s Notable Drop, Closing at 118.50 - The Dwinnex
Canada Cell And Gene Therapy CDMO Market Size & Outlook, 2030 - Grand View Research
The United States Erythropoietin Drugs Market Size & Outlook, 2030 - Grand View Research
China Biotechnology Market Size & Outlook, 2023-2030 - Grand View Research
Kuwait Gout Therapeutics Market Size & Outlook, 2023-2030 - Grand View Research
0.29%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):